• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's After-Market Session

    12/8/23 4:30:48 PM ET
    $ACRX
    $APLT
    $BWV
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACRX alert in real time by email

    Gainers

    • Onconova Therapeutics (NASDAQ:ONTX) shares moved upwards by 42.5% to $0.9 during Friday's after-market session. The company's market cap stands at $18.9 million.
    • AcelRx Pharmaceuticals (NASDAQ:ACRX) shares increased by 9.75% to $0.8. The market value of their outstanding shares is at $13.5 million.
    • IGM Biosciences (NASDAQ:IGMS) shares moved upwards by 8.87% to $7.24. The market value of their outstanding shares is at $422.7 million.
    • Applied Therapeutics (NASDAQ:APLT) stock rose 7.05% to $3.34. The company's market cap stands at $257.9 million.
    • MeiraGTx Hldgs (NASDAQ:MGTX) shares rose 6.38% to $5.0. The company's market cap stands at $317.9 million.
    • Geovax Labs (NASDAQ:GOVX) stock increased by 6.22% to $0.38. The market value of their outstanding shares is at $10.2 million.

    Losers

    • Trinity Biotech (NASDAQ:TRIB) shares declined by 18.2% to $0.45 during Friday's after-market session. The company's market cap stands at $17.1 million.
    • Milestone Scientific (AMEX:MLSS) shares declined by 12.68% to $0.62. The market value of their outstanding shares is at $44.0 million.
    • Gyre Therapeutics (NASDAQ:GYRE) shares declined by 9.68% to $18.76. The company's market cap stands at $1.4 billion.
    • Oncternal Therapeutics (NASDAQ:ONCT) shares fell 7.43% to $0.4. The company's market cap stands at $23.5 million.
    • Phio Pharma (NASDAQ:PHIO) shares fell 7.29% to $0.86. The market value of their outstanding shares is at $2.1 million.
    • Blue Water Biotech (NASDAQ:BWV) stock declined by 7.23% to $0.23. The market value of their outstanding shares is at $4.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACRX
    $APLT
    $BWV
    $GOVX

    CompanyDatePrice TargetRatingAnalyst
    GeoVax Labs Inc.
    $GOVX
    2/19/2026Buy → Hold
    D. Boral Capital
    Applied Therapeutics Inc.
    $APLT
    12/12/2025Outperform → Neutral
    Robert W. Baird
    Applied Therapeutics Inc.
    $APLT
    12/3/2025$1.00Outperform → Market Perform
    Leerink Partners
    MeiraGTx Holdings plc
    $MGTX
    11/24/2025$20.00Buy
    H.C. Wainwright
    MeiraGTx Holdings plc
    $MGTX
    10/21/2025$29.00Strong Buy
    Raymond James
    Gyre Therapeutics Inc.
    $GYRE
    10/10/2025$16.00Buy
    Jefferies
    Gyre Therapeutics Inc.
    $GYRE
    8/26/2025$18.00Buy
    H.C. Wainwright
    Phio Pharmaceuticals Corp.
    $PHIO
    6/5/2025$14.00Buy
    H.C. Wainwright
    More analyst ratings

    $ACRX
    $APLT
    $BWV
    $GOVX
    SEC Filings

    View All

    SEC Form 6-K filed by Trinity Biotech plc

    6-K - TRINITY BIOTECH PLC (0000888721) (Filer)

    3/16/26 11:32:38 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 10-K filed by Gyre Therapeutics Inc.

    10-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

    3/13/26 4:31:11 PM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gyre Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

    3/12/26 6:31:12 AM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $APLT
    $BWV
    $GOVX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Trinity Biotech Announces Collaboration with University at Buffalo to Commercialize Novel Biomarkers for Sjögren's Syndrome

    DUBLIN and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has entered into a collaboration agreement with the University at Buffalo, New York ("UB"). The partnership focuses on advancing and commercializing a suite of proprietary biomarkers for the earlier and more accurate detection of Sjögren's Syndrome, one of the most common but underdiagnosed autoimmune diseases. This collaboration is a key strategic milestone in the continued expansion of Trinity Biotech's New York State Department of Health – appr

    3/18/26 8:30:00 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Gyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment

    SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre or Gyre Therapeutics) (NASDAQ:GYRE), a San Diego-based innovative commercial stage biopharmaceutical company with operations in the United States and China, today announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted priority review status to the New Drug Application (NDA) for Hydronidone (F351) as a treatment for chronic hepatitis B (CHB)-induced liver fibrosis, which is liver damage resulting from the infection of the hepatitis B virus (HBV). This decision by CDE was made following the pre-NDA communication meeting previously announced on Januar

    3/17/26 7:00:00 AM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office

    Registration link below for Wednesday March 18, 2026 at 4 PM EDT Phio invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend this virtual event King of Prussia, Pennsylvania--(Newsfile Corp. - March 16, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will participate in a fireside chat with Steven Saltzstein, CEO, Force Family Office on Wednesday March 18, 2026

    3/16/26 11:30:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $APLT
    $BWV
    $GOVX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ACRX
    $APLT
    $BWV
    $GOVX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ACRX
    $APLT
    $BWV
    $GOVX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chairman, Pres. & CEO Bitterman Robert J bought $5,150 worth of shares (5,000 units at $1.03), increasing direct ownership by 2% to 291,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    1/2/26 4:05:06 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, Pres. & CEO Bitterman Robert J bought $5,100 worth of shares (5,000 units at $1.02), increasing direct ownership by 2% to 286,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    12/29/25 8:10:21 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, Pres. & CEO Bitterman Robert J bought $5,700 worth of shares (5,000 units at $1.14), increasing direct ownership by 2% to 281,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    11/24/25 12:54:10 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF MEDICAL OFFICER Zeldin Robert K converted options into 7,500 units of Ordinary Shares and covered exercise/tax liability with 2,952 units of Ordinary Shares, increasing direct ownership by 3% to 172,888 units (SEC Form 4)

    4 - MeiraGTx Holdings plc (0001735438) (Issuer)

    2/23/26 9:25:05 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    GENERAL COUNSEL AND SECRETARY Wollin Robert J converted options into 11,250 units of Ordinary Shares and covered exercise/tax liability with 5,949 units of Ordinary Shares, increasing direct ownership by 10% to 57,377 units (SEC Form 4)

    4 - MeiraGTx Holdings plc (0001735438) (Issuer)

    2/23/26 9:24:03 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CHIEF DEV. OFFICER Naylor Stuart converted options into 25,000 units of Ordinary Shares and covered exercise/tax liability with 11,750 units of Ordinary Shares, increasing direct ownership by 2% to 696,166 units (SEC Form 4)

    4 - MeiraGTx Holdings plc (0001735438) (Issuer)

    2/23/26 9:20:55 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    GeoVax Labs downgraded by D. Boral Capital

    D. Boral Capital downgraded GeoVax Labs from Buy to Hold

    2/19/26 8:44:06 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Applied Therapeutics downgraded by Robert W. Baird

    Robert W. Baird downgraded Applied Therapeutics from Outperform to Neutral

    12/12/25 9:22:39 AM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Applied Therapeutics downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Applied Therapeutics from Outperform to Market Perform and set a new price target of $1.00

    12/3/25 8:27:30 AM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $APLT
    $BWV
    $GOVX
    Leadership Updates

    Live Leadership Updates

    View All

    Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference

    Phio's Presentation to take place on Wednesday January 28, 2026 at 9 AM ETKing of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026 at the Borgata Hotel in Atlantic City, NJ.Robert Bitterman, CEO and Chairman of the Board of Phio Pharmaceuticals will deliver a company presentation on January 28th at 9 AM in Borgata Hotel Room #1 and the management team will be avai

    1/26/26 8:15:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Applied Therapeutics Reports Third Quarter 2025 Financial Results

    –   Update on regulatory strategy for govorestat for the treatment of CMT-SORD following receipt of Type C meeting minutes –   Meeting scheduled with the FDA in 4Q 2025 to discuss govorestat for the treatment of Classic Galactosemia –   New data on govorestat for the treatment of PMM2-CDG published in JIMD and presented at the 2025 ASHG Annual Meeting –   Announces Board of Directors Leadership Transition NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT) (the "Company"), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare diseases, today reported financial results for the third quarter ended September 30

    11/13/25 7:00:00 AM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

    King of Prussia, Pennsylvania--(Newsfile Corp. - October 31, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio is pleased to announce that David Deming has been appointed Lead Independent Director of the Board of Directors of Phio Pharmaceuticals. Mr. Deming brings over 30 years of experience in investment banking and asset management to his new role as Lead Independent Director. He was with JP Morgan for over 27 years, both in M&A and leading the Health Group in investment banking for his last 12 years there. Mr. Deming was appointed

    10/31/25 10:15:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $APLT
    $BWV
    $GOVX
    Financials

    Live finance-specific insights

    View All

    Trinity Biotech Announces Collaboration with University at Buffalo to Commercialize Novel Biomarkers for Sjögren's Syndrome

    DUBLIN and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has entered into a collaboration agreement with the University at Buffalo, New York ("UB"). The partnership focuses on advancing and commercializing a suite of proprietary biomarkers for the earlier and more accurate detection of Sjögren's Syndrome, one of the most common but underdiagnosed autoimmune diseases. This collaboration is a key strategic milestone in the continued expansion of Trinity Biotech's New York State Department of Health – appr

    3/18/26 8:30:00 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Trinity Biotech Begins Rollout of Innovative Glucose Monitoring System In Key Market Following Regulatory Approval of Next-Generation Premier Hb9210 HbA1c Column System

    Company begins roll out of innovative diabetes care HbA1c column system in Brazil Commercial leadership strengthened with key appointment DUBLIN, March 12, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has commenced the commercial rollout in Brazil of its updated laboratory blood glucose monitoring solution, the next‑generation HbA1c column system for its Premier Hb9210™ platform, following receipt of local regulatory approval. This approval enables the introduction of the Company's upgraded boronate affinity column

    3/12/26 9:00:00 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Full-year 2025 revenue increased 10% year-over-year to $116.6 million, within revised guidance range Full year 2026 revenue guidance of $100.5 to $111.0 million Entered into agreement to acquire Cullgen to gain targeted protein degradation platform and pipeline; transaction anticipated to close in the second quarter of 2026 Alignment with China's Center for Drug Evaluation (CDE) on conditional approval filing and priority review eligibility for Hydronidone, subject to formal approval; New Drug Application (NDA) submission for conditional approval expected in the first half of 2026 Completed patient enrollment in the 52-week Phase 3 pirfenidone pneumoconiosis (PD) trial(272 patients acros

    3/12/26 6:00:00 AM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $APLT
    $BWV
    $GOVX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Applied Therapeutics Inc.

    SC 13G/A - Applied Therapeutics, Inc. (0001697532) (Subject)

    11/14/24 5:47:55 PM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Trinity Biotech plc

    SC 13D/A - TRINITY BIOTECH PLC (0000888721) (Subject)

    11/14/24 5:26:28 PM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by GeoVax Labs Inc.

    SC 13G/A - GeoVax Labs, Inc. (0000832489) (Subject)

    11/14/24 5:10:48 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care